T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.76B |
| 2 |
Cigna
CI
|
+$1.44B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.26B |
| 4 |
Occidental Petroleum
OXY
|
+$763M |
| 5 |
Danaher
DHR
|
+$762M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$2.46B |
| 2 |
Wynn Resorts
WYNN
|
+$1.11B |
| 3 |
Netflix
NFLX
|
+$1.03B |
| 4 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$975M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$909M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.87% |
| 2 | Financials | 13.64% |
| 3 | Consumer Discretionary | 13.54% |
| 4 | Industrials | 10.67% |
| 5 | Technology | 10.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Lowe's Companies
LOW
$123B
| $3.15B | 0.65% |
47,107,717
-2,882,107
| -6% | -$206M |
|
27
American Airlines Group
AAL
$9.93B
| $3.11B | 0.64% |
77,925,497
-9,868,963
| -11% | -$450M |
|
28
American Tower
AMT
$78.8B
| $3.07B | 0.63% |
32,951,010
+7,417,943
| +29% | +$702M |
|
|
FISV
29
Fiserv Inc
FISV
$27.8B
| $2.95B | 0.61% |
71,152,308
+3,404,630
| +5% | +$137M |
|
30
Intuitive Surgical
ISRG
$139B
| $2.93B | 0.6% |
54,504,666
+2,624,067
| +5% | +$147M |
|
31
Salesforce
CRM
$162B
| $2.85B | 0.59% |
40,975,931
-983,917
| -2% | -$70.1M |
|
32
Thermo Fisher Scientific
TMO
$222B
| $2.77B | 0.57% |
21,350,457
-927,029
| -4% | -$121M |
|
33
Roper Technologies
ROP
$39.9B
| $2.62B | 0.54% |
15,210,950
-121,287
| -0.8% | -$21M |
|
34
AutoZone
AZO
$50.1B
| $2.62B | 0.54% |
3,930,615
+70,045
| +2% | +$47.9M |
|
35
Walt Disney
DIS
$178B
| $2.61B | 0.54% |
22,826,944
+287,627
| +1% | +$31.6M |
|
36
Alibaba
BABA
$317B
| $2.58B | 0.53% |
31,308,187
+1,441,796
| +5% | +$124M |
|
37
Elevance Health
ELV
$86.2B
| $2.57B | 0.53% |
15,670,795
+4,104,738
| +35% | +$656M |
|
38
Starbucks
SBUX
$119B
| $2.49B | 0.51% |
46,432,608
-888,900
| -2% | -$45.1M |
|
39
Wells Fargo
WFC
$265B
| $2.44B | 0.5% |
43,352,496
-2,205,157
| -5% | -$123M |
|
40
Bank of America
BAC
$447B
| $2.35B | 0.48% |
138,267,267
-8,761,251
| -6% | -$144M |
|
|
41
Netflix
NFLX
$318B
| $2.29B | 0.47% |
243,846,260
-122,934,140
| -34% | -$1.03B |
|
|
42
Bristol-Myers Squibb
BMY
$132B
| $2.23B | 0.46% |
33,502,446
+19,098,742
| +133% | +$1.26B |
|
43
ExxonMobil
XOM
$657B
| $2.2B | 0.45% |
26,401,473
-1,460,034
| -5% | -$126M |
|
44
Regeneron Pharmaceuticals
REGN
$83.2B
| $2.17B | 0.45% |
4,246,785
+370,284
| +10% | +$181M |
|
45
Incyte
INCY
$24.6B
| $2.16B | 0.44% |
20,749,529
-1,660,431
| -7% | -$172M |
|
|
BNY
46
Bank of New York Mellon
BNY
$108B
| $2.15B | 0.44% |
51,151,832
+4,520,806
| +10% | +$193M |
|
47
State Street
STT
$51.3B
| $2.13B | 0.44% |
27,633,855
-2,183,340
| -7% | -$170M |
|
48
CVS Health
CVS
$122B
| $2.11B | 0.43% |
20,080,355
+1,691,641
| +9% | +$173M |
|
49
Intercontinental Exchange
ICE
$84.5B
| $2.05B | 0.42% |
45,789,215
+2,842,295
| +7% | +$132M |
|
50
Becton Dickinson
BDX
$48.9B
| $2.01B | 0.41% |
14,555,113
+2,980,545
| +26% | +$412M |
|
Similar funds
T. Rowe Price Associates's Q2 2015 Portfolio in Review
As of Q2 2015, T. Rowe Price Associates held 2,615 positions worth $486B, up 0.44% from $484B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
T. Rowe Price Associates's Q2 2015 filing shows 76 new, 1,051 increased, 777 reduced and 79 closed positions. Its largest new stake was Allergan plc: 548,825 shares worth $570M. The largest sale was PHARMACYCLICS INC, an estimated $2.46B.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Financials and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2015 buy was Allergan plc: 548,825 shares worth $570M.
- T. Rowe Price Associates added most to Microsoft in Q2 2015, an estimated $3.76B increase.
- T. Rowe Price Associates's biggest Q2 2015 reduction was Wynn Resorts, cutting an estimated $1.11B.
- T. Rowe Price Associates fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.46B.
- T. Rowe Price Associates's ten largest holdings make up 14% of its $486B portfolio in Q2 2015.
- T. Rowe Price Associates opened 76 new positions and closed 79 in Q2 2015.
- T. Rowe Price Associates's portfolio value rose 0.44% quarter-over-quarter to $486B.
Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.